natgillin/translations-raw huggingface dataset:
Linagliptin as add-on therapy in elderly (age ≥ 70 years) with type 2 diabetes The efficacy and safety of linagliptin in elderly (age ≥ 70 years) with type 2 diabetes was evaluated in a double-blind study of 24 weeks duration.
Linagliptin kot dodatno zdravilo pri starejših (starost ≥ 70 let) s sladkorno boleznijo tipa 2 Učinkovitost in varnost linagliptina so pri starejših (starost ≥ 70 let) s sladkorno boleznijo tipa 2 ocenili v dvojno slepi študiji, ki je trajala 24 tednov.
Strong pseudo-allergic reactions were observed in dogs at medium doses, secondarily causing cardiovascular changes, which were considered dog-specific.
Pri psih so po dajanju srednje velikih odmerkov opazili izrazite psevdoalergijske reakcije s sekundarnimi učinki na srce in ožilje, ki so veljale za specifične pri psih.
Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion thus resulting in an overall improvement in the glucose homeostasis.
Linagliptin odvisno od ravni glukoze poveča izločanje insulina in zmanjša izločanje glukagona ter tako skupno izboljša homeostazo glukoze.
When Jentadueto is used with a sulphonylurea medicine or with insulin, low blood sugar can occur and your doctor may reduce the dose of your sulphonylurea or insulin.
Pri uporabi zdravila Jentadueto hkrati s sulfonilsečnino ali insulinom pa se lahko raven krvnega sladkorja zniža na premajhno vrednost, zato lahko vaš zdravnik zmanjša odmerek sulfonilsečnine ali insulina.
The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration(see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease).
Tveganje za razvoj laktacidoze je večje tudi ob sočasni nenadzorovani sladkorni bolezni, resnih okužbah, dolgotrajnem postenju ali čezmernem uživanju alkohola, dehidraciji (glejte dodatne informacije spodaj), težavah z jetri ali katerih koli bolezenskih stanjih, pri katerih je oskrba dela telesa s kisikom zmanjšana (na primer akutna huda bolezen srca).
(1) reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis, (2) in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation,
(1) z zaviranjem glukoneogeneze in glikogenolize zmanjša nastajanje glukoze v jetrih; (2) v mišicah, s povečanjem občutljivosti za insulin, izboljša periferno porabo in utilizacijo glukoze; (3) upočasni absorpcijo glukoze v črevesju.
After a median follow up of 2.2 years, linagliptin, when added to standard of care, did not increase the risk of major adverse cardiovascular events or renal outcome events.
Po mediani spremljanja 2,2 leti, linagliptin ni povečal tveganja za hude neželene srčno-žilne dogodke ali ledvične izide, kadar je bil dodan standarni terapiji.
Avoid excessive alcohol intake while taking Jentadueto since this may increase the risk of lactic acidosis (see section ‘Warnings and precautions').
Med jemanjem zdravila Jentadueto ne uživajte čezmernih količin alkohola, saj lahko to poveča tveganje za laktacidozo (glejte poglavje "Opozorila in previdnostni ukrepi").
When linagliptin was added to a sulphonylurea on a background of metformin, the incidence of hypoglycaemia was increased over that of placebo.
Če so linagliptin dodali k sulfonilsečnini ob osnovnem zdravljenju z metforminom, je bila pojavnost hipoglikemije večja kot pri placebu.
Administration of Jentadueto 2.5/1,000 mg with food resulted in no change in overall exposure of linagliptin.
Po dajanju zdravila Jentadueto po 2.5/1.000 mg s hrano se skupna izpostavljenost linagliptinu ni spremenila.
Linagliptin in combination with metformin and insulin A 24-week placebo-controlled study was conducted to evaluate the efficacy and safety of linagliptin (5 mg once daily) added to insulin with or without metformin.
Linagliptin v kombinaciji z metforminom in insulinom V s placebom nadzorovani 24-tedenski študiji so ocenili učinkovitost in varnost linagliptina (5 mg enkrat na dan), dodanega h insulinu z ali brez metformina.
In moderate renal impairment, a moderate increase in exposure of about 1.7 fold was observed compared with control.
Pri zmerni ledvični okvari je bila izpostavljenost v primerjavi s kontrolo zmerno povečana, in sicer za 1,7-krat.
If this happens you must stop taking Jentadueto and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.
V tem primeru morate prenehati jemati zdravilo Jentadueto in se takoj obrniti na zdravnika ali najbližjo bolnišnico, saj lahko laktacidoza vodi v komo.
Patients treated with linagliptin exhibited a significant mean decrease from baseline in body weight compared to a significant weight gain in patients administered glimepiride (-1.39 versus +1.29 kg).
Pri z linagliptinom zdravljenih bolnikih se je telesna masa v primerjavi z izhodiščnim stanjem pomembno zmanjšala, medtem ko se je pri bolnikih, ki so jemali glimepirid, pomembno povečala (-1,39 v primerjavi s +1,29 kg).
Bioequivalence studies in healthy subjects demonstrated that the Jentadueto (linagliptin/metformin hydrochloride) combination tablets are bioequivalent to co-administration of linagliptin and metformin hydrochloride as individual tablets.
Bioekvivalenčne študije pri zdravih prostovoljcih so pokazale, da je kombinirano zdravilo Jentadueto (linagliptin/metforminijev klorid) bioekvivalentno sočasno danim posamičnim tabletam linagliptina in metforminijevega klorida.
Glycaemic parameters at final visit (24-week study) for linagliptin and metformin, alone and in combination in patients with type 2 diabetes mellitus inadequately controlled on diet and exercise
Glikemični parametri na zadnjem obisku (24-tedenska študija) za linagliptin in metformin pri samostojni uporabi in kombinaciji pri bolnikih s sladkorno boleznijo tipa 2 in neustrezno urejeno boleznijo z dieto in telesno aktivnostjo
If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before taking Jentadueto.
Če ste v dvomih o tem, ali kaj od naštetega velja za vas, se pogovorite s svojim zdravnikom, farmacevtom ali z medicinsko sestro, preden boste vzeli zdravilo Jentadueto.
PHARMACEUTICAL FORM AND CONTENTS 60 x 1 film-coated tablets.
FARMACEVTSKA OBLIKA IN VSEBINA 60 x 1 filmsko obložena tableta.
One main metabolite with a relative exposure of 13.3% of linagliptin at steady-state was detected which was found to be pharmacologically inactive, and thus does not contribute to the plasma DPP-4 inhibitory activity of linagliptin.
V stanju dinamičnega ravnovesja so odkrili en glavni presnovek, pri katerem je bila relativna izpostavljenost linagliptinu 13,3 %, ki pa je bil farmakološko neaktiven in ni povečeval zaviralnega delovanja linagliptina na DPP-4 v plazmi.
In rats, effects on reproductive organs, thyroid and the lymphoid organs were seen at more than 1500 times human exposure.
Pri podganah so odkrili učinke na reproduktivne organe, ščitnico in limfne organe pri izpostavljenosti, ki je bila preko 1.500-krat večja od izpostavljenosti pri človeku.
Lactic acidosis is characterised by acidotic dyspnea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma.
Za laktacidozo so značilni acidozna dispneja, bolečina v trebuhu, mišični krči, astenija in hipotermija, ki ji sledi koma.
The mean HbA1c at baseline was 7.15%.
Povprečna izhodiščna vrednost HbA1c je bila 7,15 %.
For the entire treatment period (median time on treatment 5.9 years) the rate of patients with moderate or severe hypoglycaemia was 6.5% on linagliptin versus 30.9% on glimepiride, severe hypoglycaemia occurred in 0.3% of patients on linagliptin versus 2.2% on glimepiride.
V celotnem obdobju zdravljenja (mediani čas zdravljenja 5,9 let) je imelo zmerno ali hudo hipoglikemijo 6,5 % bolnikov, ki so jemali linagliptin, in 30,9 % bolnikov, ki so jemali glimepiridin, huda hipoglikemija se je pojavila pri 0,3 % bolnikov, ki so jemali linagliptin, in 2,2 % bolnikov, ki so jemali glimepiridin.
After once daily dosing of 5 mg linagliptin, steady-state plasma concentrations are reached by the third dose.
Pri dajanju po 5 mg linagliptina enkrat na dan je stanje dinamičnega ravnovesja koncentracije v plazmi doseženo do tretjega odmerka.
A statistically significant greater proportion of patients with a baseline HbA1c ≥7.0% and treated with linagliptin 5 mg achieved a target HbA1c of <7% compared to placebo.
Statistično pomembno večji delež bolnikov, zdravljenih z linagliptinom 5 mg in izhodiščno vrednostjo HbA1c ≥ 7,0 %, je v primerjavi s placebom, dosegel ciljno vrednost HbA1c < 7,0 %.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Podatki, ki niso pridobljeni v kliničnih raziskavah na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, kancerogenega potenciala, vpliva na sposobnost razmnoževanja in razvoja ne kažejo posebnega tveganja za človeka.
After oral administration of a 5 mg dose to healthy volunteers or patients, linagliptin was rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1.5 hours post-dose.
Po peroralnem dajanju odmerka po 5 mg se je linagliptin pri zdravih prostovoljcih ali bolnikih hitro absorbiral in dosegel največjo plazemsko koncentracijo (mediana Tmax) 1,5 ure po odmerku.
Adverse reactions reported in patients who received linagliptin+metformin alone (as mono-components or in combination) or as add-on to other anti-diabetic therapies in clinical trial and from post-marketing experience
Neželeni učinki, o katerih so poročali pri bolnikih, ki so prejemali linagliptin in metformin (kot monokomponento ali v kombinaciji) kot samostojno zdravljenje ali kot dodatek drugim zdravljenjem z antidiabetiki pri kliničnem preskušanju in iz izkušenj po začetku trženja
Discontinuation of therapy due to adverse events was comparable in patients who received placebo and metformin to patients treated with linagliptin and metformin (3.8% and 2.9%).
Pogostnost prekininjenih zdravljenj zaradi neželenih dogodkov je bila pri bolnikih, ki so jemali placebo in metformin, primerljiva s pogostnostjo pri tistih, ki so jemali linagliptin in metformin (3,8 % in 2,9 %).
In placebocontrolled studies, more than 1800 patients were treated with the therapeutic dose of either 2.5 mg linagliptin twice daily (or its bioequivalent of 5 mg linagliptin once daily) in combination with metformin for ≥ 12/24 weeks.
V s placebom nadzorovanih študijah se je več kot 1800 bolnikov zdravilo s terapevtskimi odmerki po 2,5 mg linagliptina dvakrat na dan (ali z bioekvivalenti po 5 mg linagliptina enkrat na dan) v kombinaciji z metforminom ≥ 12/24 tednov.
Studies in animals have shown excretion of both metformin and linagliptin into milk in lactating rats.
Študije na živalih so pokazale, da se pri podganah v laktaciji metformin in linagliptin izločata v mleko.
Multiple daily doses of linagliptin had a minimal effect on the steady-state pharmacokinetics of simvastatin, a sensitive CYP3A4 substrate, in healthy subjects.
Linagliptin je pri dajanju večkratnih dnevnih odmerkov pri zdravih prostovoljcih le minimalno vplival na farmakokinetiko simvastatina, občutljivega substrata za CYP3A4, v stanju dinamičnega ravnovesja.
In addition, linagliptin is not expected to be eliminated to a therapeutically significant degree by hemodialysis or peritoneal dialysis.
Poleg tega obseg izločanja linagliptina med hemodializo ali peritonealno dializo predvidoma ni terapevtsko pomemben.
Jentadueto is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
Zdravilo Jentuado je indicirano za zdravljenje odraslih bolnikov s sladkorno boleznijo tipa 2 kot dodatek k dieti in telesni aktivnosti za izboljšanje urejenosti glikemije:
Multiple daily doses of 5 mg linagliptin did not alter the pharmacokinetics of S(-) or R(+) warfarin, a CYP2C9 substrate, administered in a single dose.
Pri dajanju večkratnih dnevnih odmerkov linagliptina po 5 mg se farmakokinetika varfarina S(-) ali R(+), substrata za CYP2C9, po enkratnem odmerku ni spremenila.
Bottles contain 14, 60 or 180 film-coated tablets.
Plastenke vsebujejo 14, 60 ali 180 filmsko obloženih tablet.
Liver, kidneys and gastrointestinal tract are the principal target organs of toxicity in mice and rats at repeat doses of linagliptin of more than 300 times the human exposure.
Jetra, ledvice in prebavila so glavni ciljni organi za toksičnost pri miših in podganah pri ponavljajočem odmerjanju linagliptina preko 300-krat večjo izpostavljenostjo kot pri človeku.
Do not use this medicine after the expiry date which is stated on the blister, bottle and carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu, plastenki in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
C] linagliptin oral 10 mg dose, approximately 5% of the radioactivity was excreted in urine.
C] linagliptina se je približno 5 % radioaktivnosti izločilo s sečem.
- The other ingredients are: - Tablet core: arginine, copovidone, magnesium stearate, maize starch, silica, colloidal anhydrous.
- Druge sestavine zdravila so: Jedro tablete: arginin, kopovidon, magnezijev stearat, koruzni škrob, brezvodni koloidni silicijev dioksid.
Some patients have experienced the following side effects while taking Jentadueto with insulin - Uncommon: liver function disorders, constipation
Pri nekaterih bolnikih so se med jemanjem zdravila Jentadueto z insulinom pojavili naslednji neželeni učinki: - Občasni: motnje jetrnega delovanja, zaprtje
Patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin
Bolniki z neustrezno urejeno boleznijo pri dvojno kombiniranem zdravljenju z insulinom in največjim odmerkom metformina, ki ga še prenašajo
90 x 1 film-coated tablets.
90 x 1 filmsko obložena tableta.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
Študije na živalih niso pokazale neposrednih ali posrednih škodljivih učinkov na sposobnost razmnoževanja (glejte poglavje 5.3).
In patients with mild moderate and severe hepatic impairment (according to the Child-Pugh classification), mean AUC and Cmax of linagliptin were similar to healthy matched controls following administration of multiple 5 mg doses of linagliptin.
Pri bolnikih z blago, zmerno ali hudo jetrno okvaro (po Child-Pughovi klasifikaciji) sta bili srednji AUC in Cmax linagliptina po dajanju večkratnih odmerkov po 5 mg podobni kot pri ustreznih zdravih preizkušancih.
Nervous system disorders Taste disturbance common
Bolezni živčevja motnje okušanja pogosto
Animal studies with metformin do not indicate harmful effects with respect to reproductive toxicity (see section 5.3).
Študije na živalih ne kažejo škodljivih učinkov metformina na reprodukcijsko toksičnost (glejte poglavje 5.3).
Jentadueto combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class.
Zdravilo Jentadueto vsebuje kombinacijo dveh antidiabetikov s komplementarnima mehanizmoma delovanja za boljšo urejenost glikemije pri bolnikih s sladkorno boleznijo tipa 2: linagliptin, zaviralec dipeptidil-peptidaze 4 (DPP-4), in metforminijev klorid, učinkovino iz skupine bigvanidov.
An embryofetal development study in pregnant rats did not indicate a teratogenic effect attributed to the co-administration of linagliptin and metformin at AUC exposure levels up to 4 and 30 times human exposure, respectively.
Študija o učinkih na zarodek in plod pri brejih podganah ni kazala na teratogene učinke sočasnega dajanja linagliptina in metformina pri izpostavljenosti ravnem AUC, ki so bile do 4-krat oziroma do 30-krat večje kot pri človeku.
Pack sizes of 14, 60 and 180 film-coated tablets.
Velikosti pakiranja po 14, 60 in 180 filmsko obloženih tablet.
The safety of linagliptin 2.5 mg twice daily (or its bioequivalent of 5 mg once daily) in combination with metformin has been evaluated in over 6800 patients with type 2 diabetes mellitus.
Varnost linagliptina v odmerkih po 2,5 mg dvakrat na dan (ali bioekvivalentih po 5 mg enkrat na dan) v kombinaciji z metforminom so ocenili pri več kot 6800 bolnikih s sladkorno boleznijo tipa 2.
Symptoms of lactic acidosis include: - vomiting - stomach ache (abdominal pain) - muscle cramps - a general feeling of not being well with severe tiredness - difficulty in breathing - reduced body temperature and heartbeat
Simptomi laktacidoze vključujejo: - bruhanje, - bolečino v trebuhu (abdominalna bolečina), - mišične krče, - splošno slabo počutje s hudo utrujenostjo, - težave z dihanjem, - znižano telesno temperaturo in počasen srčni utrip.
Plasma AUC of linagliptin increased approximately 33% following 5 mg doses at steady-state compared to the first dose.
AUC linagliptina v plazmi se je v stanju dinamičnega ravnovesja po 5-mg odmerkih povečala za 33 % v primerjavi z njeno vrednostjo po prvem odmerku.
Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis.
Intravaskularna aplikacija jodiranih kontrastnih sredstev lahko povzroči nefropatijo zaradi kontrastnega sredstva, ki povzroči kopičenje metformina in povečano tveganje laktacidoze.
It is not known whether linagliptin is excreted into human milk.
Ni znano, ali se tudi linagliptin izloča v materino mleko.
Exposure in T2DM patients with severe RI was increased by about 1.4 fold compared to T2DM patients with normal renal function.
Pri bolnikih s sladkorno boleznijo tipa 2 in hudo ledvično okvaro je bila izpostavljenost približno 1,4-krat večja kot pri bolnikih s sladkorno boleznijo tipa 2 z normalnim ledvičnim delovanjem.
Steady-state predictions for AUC of linagliptin in patients with ESRD indicated comparable exposure to that of patients with moderate or severe renal impairment.
Napovedi za AUC linagliptina v stanju dinamičnega ravnovesja pri bolnikih s končno ledvično odpovedjo so kazale na primerljivo izpostavljenost kot pri tistih z zmerno ali hudo ledvično okvaro.
100 x 1 film-coated tablets.
100 x 1 filmsko obložena tableta.
Metformin hydrochloride is excreted unchanged in the urine.
Metforminijev klorid se nespremenjen izloči s sečem.
Among patients who were using insulin at baseline, the incidence of severe hypoglycaemia was 4.4% in linagliptin-treated patients and 4.9% in placebo treated patients.
Med bolniki, ki so ob izhodišču jemali insulin, je bila pojavnost hude hipoglikemije 4,4 % pri bolnikih, ki so se zdravili z linagliptinom, in 4,9 % pri bolnikih, ki so se zdravili s placebom.
Food decreases the extent and slightly delays the absorption of metformin hydrochloride.
Hrana zmanjša obseg absorpcije metforminijevega klorida in jo nekoliko upočasni.
These hormones are rapidly degraded by the enzyme DPP-4.
Encim DPP-4 oba hormona hitro razgradi.
Linagliptin trough concentrations were also measured in elderly (age ≥ 70 years) with type 2 diabetes in a phase III study of 24 weeks duration.
Najmanjše koncentracije linagliptina pred naslednjim odmerkom so merili tudi starejšim s sladkorno boleznijo tipa 2 (starost ≥ 70 let), in sicer v 24-tedenski študiji III. faze.
• Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.
• zaviralci OCT1 (npr. verapamil) lahko zmanjša učinkovitost metformina;
When linagliptin and metformin were administered in combination with insulin, hypoglycaemia was the most frequently reported adverse event, but occurred at comparable rate when placebo and metformin were combined with insulin (linagliptin plus metformin plus insulin 29.5% and 30.9% in the placebo plus metformin plus insulin group) with a low rate of severe (requiring assistance) episodes (1.5% and 0.9%).
Pri zdravljenju z linagliptinom in metforminom v kombinaciji z insulinom je bil najpogostejši neželeni dogodek, o katerem so poročali, hipoglikemija, vendar je do njega prišlo v primerljivem obsegu kot pri placebu in metforminom z insulinom (29,5 % za linagliptin + metformin + insulin in 30,9 % za skupino, ki je prejemala placebo + metformin + insulin); stopnja hudih epizod (kjer je bila potrebna pomoč) je bila nizka (1,5 % in 0,9 %).
- High-Density PolyEthylene (HDPE) bottle with plastic screw cap and a seal liner (aluminiumpolyester foil laminate) and a silica gel desiccant.
- Plastenka iz polietilena visoke gostote (HDPE) s plastično navojno zaporko, podlogo tesnila (laminat iz aluminjasto poliesterske folije) in sredstvom za sušenje s silicijevim dioksidom.
When linagliptin plus metformin hydrochloride is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia (see section 4.4).
Pri uporabi linagliptina in metforminijevega klorida v kombinaciji z insulinom je včasih potreben manjši odmerek insulina, da bi zmanjšali nevarnost hipoglikemije (glejte poglavje 4.4).
Linagliptin cardiovascular and renal safety study (CARMELINA) The CARMELINA study evaluated the cardiovascular and renal safety of linagliptin versus placebo in patients with type 2 diabetes and with increased CV risk evidenced by a history of established macrovascular or renal disease (see section 5.1).
Študija o srčno-žilni in ledvični varnosti linagliptina (CARMELINA) Študija CARMELINA je ocenjevala srčno-žilno in ledvično varnost linagliptina v primerjavi s placebom pri bolnikih s sladkorno boleznijo tipa 2 in povečanim srčno-žilnim tveganjem, glede na anamnezo ugotovljenih makrovaskularnih ali ledvičnih bolezni (glejte poglavje 5.1).
Clinical experience with Jentadueto in patients with hepatic impairment is lacking.
Z uporabo zdravila Jentadueto pri bolnikih z jetrno okvaro ni kliničnih izkušenj.
When linagliptin plus metformin hydrochloride is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4).
Če jemljejo linagliptin in metformininjev klorid v kombinaciji s sulfonilsečnino, je včasih potreben manjši odmerek sulfonilsečnine, da bi zmanjšali nevarnost hipoglikemije (glejte poglavje 4.4).
The two active substances work together to control blood sugar levels in adult patients with a form of diabetes called ‘type 2 diabetes mellitus'.
Dve zdravilni učinkovini urejata raven krvnega sladkorja pri odraslih bolnikih s sladkorno boleznijo tipa 2.
Following administration of a supratherapeutic dose of 10 mg linagliptin concomitantly with 40 mg of simvastatin daily for 6 days, the plasma AUC of simvastatin was increased by 34%, and the plasma Cmax by 10%.
Po 6-dnevnem sočasnem dajanju supraterapevtskega odmerka linagliptina po 10 mg in 40 mg simvastatina na dan se je AUC simvastatina v plazmi povečala za 34 %, njegova Cmax v plazmi pa za
In clinical trials, the incidence rates of hypoglycemia were comparably low in patients taking linagliptin in combination with metformin or metformin alone.
V kliničnih preskušanjih je bila stopnja pojavnosti hipoglikemije pri bolnikih, ki so jemali linagliptin v kombinaciji z metforminom in tistih, ki so jemali samo metformin, primerljivo nizka.
Jentadueto is also available in plastic bottles with plastic screw cap and a silica gel desiccant.
Zdravilo Jentadueto je na voljo tudi v plastenkah s plastično navojno zaporko in sredstvom za sušenje s silicijevim dioksidom.
- Linagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4
- Linagliptin je zdravilna učinkovina iz skupine zaviralcev DPP-4 (zaviralci dipeptidil peptidaze-4).
In vivo assessment of interactions
Ocena medsebojnega delovanja in vivo
Your doctor will decide when you must stop and when to restart your treatment with Jentadueto.
Zdravnik se bo odločil, kdaj morate z jemanjem zdravila Jentadueto prenehati in kdaj lahko nadaljujete.